Meningococcal Vaccine Could Protect Against 91% of Targeted Bacterial Strains

News   Nov 23, 2017 | Original story from the American Society for Microbiology

 
Meningococcal Vaccine Could Protect Against 91% of Targeted Bacterial Strains
 
 
 

RELATED ARTICLES

Zika Vaccine Trials Provide Promising Results

News

Researchers report that an investigational Zika vaccine was well-tolerated and stimulated potentially protective immune responses in three Phase 1 clinical trials,

READ MORE

Malvern Panalytical Wins Innovate UK Grant

News

Funding for 3-year-long project to lead biopharmaceutical consortium on aggregation analytics.

READ MORE

Lonza, Akouos and MEE Announce Strategic Gene Therapy License Agreements on Hearing and Balance Disorders

News

Lonza and Massachusetts Eye and Ear (MEE) grant Akouos exclusive licenses to proprietary ancestral AAV (Anc-AAV) vectors for all hearing and balance disorders.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Biopharma

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE